Ireland
--:--IST
Recruiting Observational

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy

NCT06352307 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2024-04-09
Last updated
2024-07-12

Condition(s) studied

Arrhythmogenic Cardiomyopathy

Investigational drug(s) / intervention(s)

Diagnosis of ACM

Diagnosis of ACM: Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.

Study summary

This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years old. * The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing. * Patients or their families agreed to participate in the study and authorized informed consent. Exclusion Criteria: * Incomplete clinical data. * Do not agree to the inclusion or refuse to authorize the informed consent.

Primary outcome measure(s)

  • Change in the incidence of mortality rate — At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year.
    The survival status will be obtained from the medical records and phone calls to patients or their family members.

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Xi'an Jiantong University Xi'an Shaanxi Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06352307 on ClinicalTrials.gov ↗ ← All trials in China